This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
CRA experts advised two parties during both the CMA’s investigation and CAT Appeals, assessing the economic evidence and providing expert testimony on what prices could be considered excessive (or, to the contrary, consistent with competitive outcomes) in the UK market for Liothyronine tablets.
We are pleased to present the latest edition of CRA’s IP Literature Watch. This issue contains pieces on antitrust & IP, licensing, litigation, innovation, law...
We are pleased to present the latest edition of CRA’s IP Literature Watch. This issue contains pieces on antitrust & IP, licensing, litigation, innovation, law...
Dynamic competition is becoming an ever more important aspect of merger review processes worldwide. Agencies focus closely on how merging Parties think about...
CRA is a proud sponsor of the workshop focusing on innovation, industrial policy and economic growth Oli Latham is a panelist on “Competition Policy,...
